UCB announces FDA approval of ZILBRYSQ for the Treatment of Adults with Generalized Myasthenia Gravis
On the 17th of October 2023, UCB (Euronext Brussels: UCB) made an announcement regarding the approval of ZILBRYSQ® (zilucoplan) by the US FDA for the management of generalized myasthenia gravis (gMG) in adult patients who test positive for anti-acetylcholine receptor (AChR) antibodies.
ZILBRYSQ, functioning as a complement C5 inhibitor, effectively hinders damage to the neuromuscular junction caused by complement activation, owing to its precise mode of action. Unlike monoclonal antibody C5 inhibitors, ZILBRYSQ, being a peptide-based medication, can be concurren...